Explore our pipeline of therapies targeting underserved areas of ophthalmology:
- OCU300For ocular graft versus host disease (oGVHD)
- OCU310For treatment of dry eye disease (DED)
- OCU100For treatment of retinis pigmentosa
- OCU200For wet age-related macular degneration
- OCU400For treatment of inherited retinal disorders
Addressing a common complication that occurs in 40-60% of patients who have undergone allogenic hemotological stem cell transplantation, or bone marrow transplants.
In development under the FDA’s 505(b)(2) regulatory pathway
Learn More About OCU300Addressing a common yet under-diagnosed ocular disorder that affects millions of adults in the US and its prevalence increases with age.
In development under the FDA’s 505(b)(2) regulatory pathway
Learn More About OCU310Addressing a group of inherited diseases that cause progressive retinal degeneration, affecting approximately 100,000 people in the US and similar number in Europe.
Learn More About OCU100Addressing the leading cause of vision loss in people over the age of 60, where abnormal blood vessels grow under the retina and leak blood and proteins.
Learn More About OCU200Addressing a range of genetically diverse inherited degenerative retinal diseases.
Learn More About OCU400Press Releases
Explore our pipeline of therapies targeting underserved areas of ophthalmology:
Addressing a common complication that occurs in 40-60% of patients who have undergone allogenic hemotological stem cell transplantation, or bone marrow transplants.
In development under the FDA’s 505(b)(2) regulatory pathway
Learn More About OCU300Addressing a common yet under-diagnosed ocular disorder that affects millions of adults in the US and its prevalence increases with age.
In development under the FDA’s 505(b)(2) regulatory pathway
Learn More About OCU310Addressing a range of genetically diverse inherited degenerative retinal diseases.
Learn More About OCU400
